Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | CNR1 | P21554 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 4/20 | 0.40 |
| ▸ | LMNA | P02545 | 3/20 | 0.40 |
| ▸ | HTT | P42858 | 2/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | HTR1A | P08908 | 1/20 | 0.38 |
| ▸ | DRD2 | P14416 | 1/20 | 0.38 |
| ▸ | DRD4 | P21917 | 1/20 | 0.38 |
| ▸ | GRM5 | P41594 | 1/20 | 0.38 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.38 |
| ▸ | CCR1 | P32246 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29924612 | 1.00 | ALDH1A1 (0.41) | ALDH1A1SMN1; SMN2MEN1KMT2ANPC1 | |
| SCHEMBL14761667 | 0.83 | ALDH1A1 (0.42) | ALDH1A1SMN1; SMN2MEN1KMT2ANPC1 | |
| SCHEMBL439379 | 0.83 | ALDH1A1 (0.41) | ALDH1A1SMN1; SMN2MEN1KMT2ANPC1 | |
| SCHEMBL29668566 | 0.83 | ALDH1A1 (0.41) | ALDH1A1SMN1; SMN2MEN1KMT2ANPC1 | |
| SCHEMBL20140095 | 0.83 | HTR1A (0.54) | ALDH1A1SMN1; SMN2MEN1KMT2ANPC1 | |
| SCHEMBL17844401 | 0.82 | ALDH1A1 (0.46) | ALDH1A1SMN1; SMN2MEN1KMT2ANPC1 | |
| SCHEMBL20280124 | 0.81 | GRM1 (0.58) | CNR1GRM5GRM1 | |
| SCHEMBL29924281 | 0.81 | ALDH1A1 (0.45) | ALDH1A1SMN1; SMN2MEN1KMT2ANPC1 | |
| SCHEMBL26117408 | 0.80 | HTR1A (0.48) | ALDH1A1SMN1; SMN2MEN1KMT2ANPC1 | |
| SCHEMBL16422799 | 0.80 | GRM1 (0.41) | ALDH1A1SMN1; SMN2MEN1KMT2ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240034725-A1 | GLP-1 RECEPTOR AGONISTS AND USES THEREOF | PFIZER INC. (US) | 2024-02-01 | — | — | US | disclosed |
| US-11802121-B2 | GLP-1 receptor agonists and uses thereof | PFIZER INC. (US) | 2023-10-31 | — | — | US | disclosed |
| US-20230124938-A1 | GLP-1 RECEPTOR AGONISTS AND USES THEREOF | PFIZER INC. (US) | 2023-04-20 | — | — | US | disclosed |
| EP-3555064-B9 | GLP-1 RECEPTOR AGONISTS AND USES THEREOF | PFIZER (US) | 2023-03-01 | — | — | EP | disclosed |
| WO-2022228490-A1 | POLYCYCLIC DERIVATIVE MODULATOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 上海翰森生物医药科技有限公司 | 2022-11-03 | — | — | WO | disclosed |
| US-20210047298-A1 | GLP-1 RECEPTOR AGONISTS AND USES THEREOF | PFIZER INC. (US) | 2021-02-18 | — | — | US | disclosed |
| US-10851081-B2 | GLP-1 receptor agonists and uses thereof | PFIZER INC. (US) | 2020-12-01 | — | — | US | disclosed |
| US-20200255406-A1 | GLP-1 RECEPTOR AGONISTS AND USES THEREOF | PFIZER INC. (US) | 2020-08-13 | — | — | US | disclosed |
| US-10669259-B2 | GLP-1 receptor agonists and uses thereof | PFIZER INC. (US) | 2020-06-02 | — | — | US | disclosed |
| EP-3555064-A1 | GLP-1 RECEPTOR AGONISTS AND USES THEREOF | Pfizer Inc. (US) | 2019-10-23 | — | — | EP | disclosed |
| US-20190119255-A1 | GLP-1 Receptor Agonists and Uses Thereof | PFIZER INC. (US) | 2019-04-25 | — | — | US | disclosed |
| US-10208019-B2 | GLP-1 receptor agonists and uses thereof | PFIZER INC. (US) | 2019-02-19 | — | — | US | disclosed |
| EP-2832728-B1 | TRIAZINONE COMPOUND AND T-TYPE CALCIUM CHANNEL INHIBITOR | NISSAN CHEMICAL IND LTD (JP) | 2018-09-05 | — | — | EP | disclosed |
| US-20180170908-A1 | GLP-1 Agonists and Uses Thereof | PFIZER INC. (US) | 2018-06-21 | — | — | US | disclosed |
| WO-2018109607-A1 | GLP-1 RECEPTOR AGONISTS AND USES THEREOF | PFIZER INC. (US) | 2018-06-21 | — | — | WO | disclosed |
| US-9403798-B2 | Triazinone compound and T-type calcium channel inhibitor | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2016-08-02 | — | — | US | disclosed |
| US-20150065705-A1 | TRIAZINONE COMPOUND AND T-TYPE CALCIUM CHANNEL INHIBITOR | NISSAN CHEMICAL CORPORATION (JP) | 2015-03-05 | — | — | US | disclosed |
| EP-2832728-A1 | TRIAZINONE COMPOUND AND T-TYPE CALCIUM CHANNEL INHIBITOR | Nissan Chemical Industries, Ltd. (JP) | 2015-02-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10669259-B2 | GLP-1 receptor agonists and uses thereof | GLP1R, GIPR, GPR119 | ALDH1A1 747/4885SMN1; SMN2 3802/4885MEN1 1779/4885 |
| US-20180170908-A1 | GLP-1 Agonists and Uses Thereof | GLP1R, GIPR, GPR119 | ALDH1A1 765/4885SMN1; SMN2 3446/4885MEN1 1309/4885 |
| US-10851081-B2 | GLP-1 receptor agonists and uses thereof | GLP1R, GIPR, GPR119 | ALDH1A1 747/4885SMN1; SMN2 3802/4885MEN1 1779/4885 |
| US-20190119255-A1 | GLP-1 Receptor Agonists and Uses Thereof | GLP1R, GIPR, GPR119 | ALDH1A1 747/4885SMN1; SMN2 3802/4885MEN1 1779/4885 |
| US-11802121-B2 | GLP-1 receptor agonists and uses thereof | GLP1R, GIPR, GPR119 | ALDH1A1 747/4885SMN1; SMN2 3802/4885MEN1 1779/4885 |
| US-10208019-B2 | GLP-1 receptor agonists and uses thereof | GLP1R, GIPR, GPR119 | ALDH1A1 747/4885SMN1; SMN2 3802/4885MEN1 1779/4885 |
| US-20210047298-A1 | GLP-1 RECEPTOR AGONISTS AND USES THEREOF | GLP1R, GIPR, GPR119 | ALDH1A1 747/4885SMN1; SMN2 3802/4885MEN1 1779/4885 |
| US-20150065705-A1 | TRIAZINONE COMPOUND AND T-TYPE CALCIUM CHANNEL INHIBITOR | CACNA1E, CACNA1I, CACNA1G | ALDH1A1 2675/4885SMN1; SMN2 1034/4885MEN1 3499/4885 |
| US-20240034725-A1 | GLP-1 RECEPTOR AGONISTS AND USES THEREOF | GLP1R, GIPR, GPR119 | ALDH1A1 747/4885SMN1; SMN2 3802/4885MEN1 1779/4885 |
| US-20200255406-A1 | GLP-1 RECEPTOR AGONISTS AND USES THEREOF | GLP1R, GIPR, GPR119 | ALDH1A1 747/4885SMN1; SMN2 3802/4885MEN1 1779/4885 |
| US-20230124938-A1 | GLP-1 RECEPTOR AGONISTS AND USES THEREOF | GLP1R, GIPR, GPR119 | ALDH1A1 747/4885SMN1; SMN2 3802/4885MEN1 1779/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.